178 related articles for article (PubMed ID: 23614054)
21. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice.
Aliotta JM; Pereira M; Wen S; Dooner MS; Del Tatto M; Papa E; Goldberg LR; Baird GL; Ventetuolo CE; Quesenberry PJ; Klinger JR
Cardiovasc Res; 2016 Jun; 110(3):319-30. PubMed ID: 26980205
[TBL] [Abstract][Full Text] [Related]
22. NAD(P)H oxidase subunit p47phox is elevated, and p47phox knockout prevents diaphragm contractile dysfunction in heart failure.
Ahn B; Beharry AW; Frye GS; Judge AR; Ferreira LF
Am J Physiol Lung Cell Mol Physiol; 2015 Sep; 309(5):L497-505. PubMed ID: 26209274
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension.
Gray EA; Tsuchimochi H; Pearson JT; Sonobe T; Fujii Y; Yoshimoto M; Umetani K; Shirai M; Schwenke DO
J Synchrotron Radiat; 2013 Sep; 20(Pt 5):756-64. PubMed ID: 23955040
[TBL] [Abstract][Full Text] [Related]
24. Effects of acute steroid administration on ventilatory and peripheral muscles in rats.
Nava S; Gayan-Ramirez G; Rollier H; Bisschop A; Dom R; de Bock V; Decramer M
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1888-96. PubMed ID: 8665051
[TBL] [Abstract][Full Text] [Related]
25. Diaphragm atrophy and weakness in cortisone-treated rats.
Moore BJ; Miller MJ; Feldman HA; Reid MB
J Appl Physiol (1985); 1989 Dec; 67(6):2420-6. PubMed ID: 2606849
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor.
Qin L; D'Alessandro-Gabazza CN; Aoki S; Gil-Bernabe P; Yano Y; Takagi T; Boveda-Ruiz D; Ramirez Marmol AY; San Martin Montenegro VT; Toda M; Miyake Y; Taguchi O; Takei Y; Morser J; Gabazza EC
J Thromb Haemost; 2010 Apr; 8(4):808-16. PubMed ID: 20088932
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy.
Gilliam LA; Moylan JS; Callahan LA; Sumandea MP; Reid MB
Muscle Nerve; 2011 Jan; 43(1):94-102. PubMed ID: 21171100
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.
Jasmin JF; Lucas M; Cernacek P; Dupuis J
Circulation; 2001 Jan; 103(2):314-8. PubMed ID: 11208695
[TBL] [Abstract][Full Text] [Related]
29. Nox4 Knockout Does Not Prevent Diaphragm Atrophy, Contractile Dysfunction, or Mitochondrial Maladaptation in the Early Phase Post-Myocardial Infarction in Mice.
Hahn D; Kumar RA; Muscato DR; Ryan TE; Schröder K; Ferreira LF
Cell Physiol Biochem; 2021 Aug; 55(4):489-504. PubMed ID: 34416105
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic and metabolic features of mouse diaphragm and gastrocnemius muscles in chronic lung carcinogenesis: influence of underlying emphysema.
Salazar-Degracia A; Blanco D; Vilà-Ubach M; de Biurrun G; de Solórzano CO; Montuenga LM; Barreiro E
J Transl Med; 2016 Aug; 14(1):244. PubMed ID: 27549759
[TBL] [Abstract][Full Text] [Related]
31. Skeletal myofiber VEGF deficiency leads to mitochondrial, structural, and contractile alterations in mouse diaphragm.
Cannon DT; Rodewohl L; Adams V; Breen EC; Bowen TS
J Appl Physiol (1985); 2019 Nov; 127(5):1360-1369. PubMed ID: 31487223
[TBL] [Abstract][Full Text] [Related]
32. Janus kinase inhibition prevents cancer- and myocardial infarction-mediated diaphragm muscle weakness in mice.
Smith IJ; Roberts B; Beharry A; Godinez GL; Payan DG; Kinsella TM; Judge AR; Ferreira LF
Am J Physiol Regul Integr Comp Physiol; 2016 Apr; 310(8):R707-10. PubMed ID: 26864813
[TBL] [Abstract][Full Text] [Related]
33. Time course and mechanisms of left ventricular systolic and diastolic dysfunction in monocrotaline-induced pulmonary hypertension.
Correia-Pinto J; Henriques-Coelho T; Roncon-Albuquerque R; Lourenço AP; Melo-Rocha G; Vasques-Nóvoa F; Gillebert TC; Leite-Moreira AF
Basic Res Cardiol; 2009 Sep; 104(5):535-45. PubMed ID: 19288153
[TBL] [Abstract][Full Text] [Related]
34. Anti-inflammatory nutrition with high protein attenuates cardiac and skeletal muscle alterations in a pulmonary arterial hypertension model.
Vinke P; Bowen TS; Boekschoten MV; Witkamp RF; Adams V; van Norren K
Sci Rep; 2019 Jul; 9(1):10160. PubMed ID: 31308383
[TBL] [Abstract][Full Text] [Related]
35. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
36. Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice.
Aliotta JM; Pereira M; Amaral A; Sorokina A; Igbinoba Z; Hasslinger A; El-Bizri R; Rounds SI; Quesenberry PJ; Klinger JR
Cardiovasc Res; 2013 Dec; 100(3):354-62. PubMed ID: 23867631
[TBL] [Abstract][Full Text] [Related]
37. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
38. Characterization of erectile function in monocrotaline-treated pulmonary hypertensive rats.
Gur S; Kadowitz PJ; Thammasitboon S; Lasky JA; Hellstrom WJ
J Androl; 2009; 30(5):495-504. PubMed ID: 19201699
[TBL] [Abstract][Full Text] [Related]
39. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats.
Tofovic SP; Salah EM; Mady HH; Jackson EK; Melhem MF
J Cardiovasc Pharmacol; 2005 Oct; 46(4):430-7. PubMed ID: 16160593
[TBL] [Abstract][Full Text] [Related]
40. Exaggerated pulmonary hypertension with monocrotaline in rats susceptible to chronic mountain sickness.
Colice GL; Hill N; Lee YJ; Du H; Klinger J; Leiter JC; Ou LC
J Appl Physiol (1985); 1997 Jul; 83(1):25-31. PubMed ID: 9216940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
